North America Bioreactors market growth was valued at USD 1.8 billion in 2019 and is expected to witness over 13.5% CAGR from 2020 to 2026. Segmental analysis based on Product type, Cell, Molecule & End-Use.

North America Bioreactors Market Size & Share | 2020 to 2026

North America Bioreactors Market Share By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), Product Type (Single-use, Reusable), Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By End-use (R&D Organizations, Biopharma Manufacturers, CMOs), Industry Analysis Report, Country Outlook (U.S. Canada), Application Potential, Competitive Market Share & Forecast, 2020 - 2026

Report Content

Chapter 1.&nbsp;&nbsp;&nbsp;&nbsp; Methodology

1.1.&nbsp;&nbsp; Definition and forecast parameters

1.1.1.&nbsp; Definitions

1.1.2.&nbsp; Methodology and forecast parameters

1.2.&nbsp;&nbsp; Data sources&nbsp;

1.3.&nbsp;&nbsp; References &amp; sources

1.3.1.&nbsp; Secondary

1.3.2.&nbsp; Primary

Chapter 2.&nbsp;&nbsp;&nbsp;&nbsp; Executive Summary

2.1.&nbsp;&nbsp; North America bioreactors industry summary, 2015 &ndash; 2026

2.1.1.&nbsp; Country trends

2.1.2.&nbsp; Product type trends

2.1.3.&nbsp; Cell trends

2.1.4.&nbsp; Molecule trends

2.1.5.&nbsp; End-use trends

Chapter 3.&nbsp;&nbsp;&nbsp;&nbsp; Industry Insights

3.1.&nbsp;&nbsp; Industry segmentation

3.2.&nbsp;&nbsp; Industry outlook, 2015 - 2026

3.3.&nbsp;&nbsp; Major factor analysis

3.3.1.&nbsp; Drivers

3.3.1.1.&nbsp;&nbsp; Growing pharmaceutical and biotechnology industry in the region

3.3.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rising government initiatives in the region

3.3.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Technological advancements in bioprocessing systems

3.3.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rising demand for vaccines and cell-targeted therapies

3.3.2.&nbsp; Restraints &amp; challenges

3.3.2.1.&nbsp;&nbsp; Limitations associated with single-use bioreactors

3.3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concerns regarding extractables and leachables

3.3.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stringent regulatory framework

3.4.&nbsp;&nbsp; Analysis of COVID-19 impact on the industry

3.5.&nbsp;&nbsp; Porter&rsquo;s analysis

3.6.&nbsp;&nbsp; Competitive review, 2019

3.7.&nbsp;&nbsp; PEST analysis

Chapter 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; North America Bioreactors Market Share, By Product Type

4.1.&nbsp;&nbsp; Key trends in North America bioreactors, by product type

4.2.&nbsp;&nbsp; Single-use

4.2.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

4.3.&nbsp;&nbsp; Reusable

4.3.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

Chapter 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; North America Bioreactors Market Size, By Cell

5.1.&nbsp;&nbsp; Key trends in North America bioreactors, by cell

5.2.&nbsp;&nbsp; Mammalian cells

5.2.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

5.3.&nbsp;&nbsp; Bacterial cells

5.3.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

5.4.&nbsp;&nbsp; Yeast cells

5.4.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

5.5.&nbsp;&nbsp; Others

5.5.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

Chapter 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; North America Bioreactors Market Growth, By Molecule

6.1.&nbsp;&nbsp; Key trends in North America bioreactors, by molecule

6.2.&nbsp;&nbsp; Monoclonal antibodies

6.2.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

6.3.&nbsp;&nbsp; Vaccines

6.3.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

6.4.&nbsp;&nbsp; Recombinant proteins

6.4.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

6.5.&nbsp;&nbsp; Stem cells

6.5.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

6.6.&nbsp;&nbsp; Gene therapy

6.6.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

6.7.&nbsp;&nbsp; Others

6.7.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

Chapter 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; North America Bioreactors Market Forecast, By End-use

7.1.&nbsp;&nbsp; Key trends in North America bioreactors, by End-use

7.2.&nbsp;&nbsp; R&amp;D Organizations

7.2.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

7.3.&nbsp;&nbsp; Biopharma Manufacturers

7.3.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

7.4.&nbsp;&nbsp; CMOs

7.4.1.&nbsp; Market estimates and forecast, by country, 2015 &ndash; 2026 (USD Million)

Chapter 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; North America Bioreactors Market Trends, By Country

8.1.&nbsp;&nbsp; Key trends in North America bioreactors, by country

8.2.&nbsp;&nbsp; U.S.

8.2.1.&nbsp;&nbsp; Market estimates and forecast, by product type, 2015 &ndash; 2026 (USD Million)

8.2.2.&nbsp; Market estimates and forecast, by cells, 2015 &ndash; 2026 (USD Million)

8.2.3.&nbsp; Market estimates and forecast, by molecule, 2015 &ndash; 2026 (USD Million)

8.2.4.&nbsp; Market estimates and forecast, by end-use, 2015 &ndash; 2026 (USD Million)

8.3.&nbsp;&nbsp; Canada

8.3.1.&nbsp;&nbsp; Market estimates and forecast, by product type, 2015 &ndash; 2026 (USD Million)

8.3.2.&nbsp; Market estimates and forecast, by cells, 2015 &ndash; 2026 (USD Million)

8.3.3.&nbsp; Market estimates and forecast, by molecule, 2015 &ndash; 2026 (USD Million)

8.3.4.&nbsp; Market estimates and forecast, by end-use, 2015 &ndash; 2026 (USD Million)

Chapter 9.&nbsp;&nbsp;&nbsp;&nbsp; Company Profiles

9.1.&nbsp;&nbsp; Applikon Biotechnology, Inc. (Getinge AB)

9.1.1.&nbsp;&nbsp; Business overview

9.1.2.&nbsp; Financial data

9.1.3.&nbsp; Product landscape

9.1.4.&nbsp; Strategic outlook

9.2.&nbsp;&nbsp; Eppendorf AG

9.2.1.&nbsp;&nbsp; Business overview

9.2.2.&nbsp; Financial data

9.2.3.&nbsp; Product landscape

9.2.4.&nbsp; Strategic outlook

9.3.&nbsp;&nbsp; Cytiva

9.3.1.&nbsp;&nbsp; Business overview

9.3.2.&nbsp; Financial data

9.3.3.&nbsp; Product landscape

9.3.4.&nbsp; Strategic outlook

9.4.&nbsp;&nbsp; GEA Group Aktiengesellschaft

9.4.1.&nbsp;&nbsp; Business overview

9.4.2.&nbsp; Financial data

9.4.3.&nbsp; Product landscape

9.4.4.&nbsp; Strategic outlook

9.5.&nbsp;&nbsp; Merck Group

9.5.1.&nbsp;&nbsp; Business overview

9.5.2.&nbsp; Financial data

9.5.3.&nbsp; Product landscape

9.5.4.&nbsp; Strategic outlook

9.6.&nbsp;&nbsp; Pierre Guerin Sas

9.6.1.&nbsp;&nbsp; Business overview

9.6.2.&nbsp; Financial data

9.6.3.&nbsp; Product landscape

9.6.4.&nbsp; Strategic outlook

9.7.&nbsp;&nbsp; PBS Biotech

9.7.1.&nbsp;&nbsp; Business overview

9.7.2.&nbsp; Financial data

9.7.3.&nbsp; Product landscape

9.7.4.&nbsp; Strategic outlook

9.8.&nbsp;&nbsp; Sartorius Group

9.8.1.&nbsp;&nbsp; Business overview

9.8.2.&nbsp; Financial data

9.8.3.&nbsp; Product landscape

9.8.4.&nbsp; Strategic outlook

9.9.&nbsp;&nbsp; Shanghai Bailun Biotechnology co., Ltd.

9.9.1.&nbsp;&nbsp; Business overview

9.9.2.&nbsp; Financial data

9.9.3.&nbsp; Product landscape

9.9.4.&nbsp; Strategic outlook

9.10. Solaris Biotechnology Srl

9.10.1. Business overview

9.10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial data

9.10.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product landscape

9.10.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strategic outlook

9.11. Thermo Fisher Scientific

9.11.1. Business overview

9.11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial data

9.11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Product landscape

9.11.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strategic outlook 
&nbsp;